

Terry A Jacobson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7145899/publications.pdf>

Version: 2024-02-01

181
papers

19,638
citations

11608

70
h-index

11288

136
g-index

185
all docs

185
docs citations

185
times ranked

17777
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. <i>JAMA Network Open</i> , 2022, 5, e2148172.	2.8	11
2	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. <i>Journal of the American Heart Association</i> , 2022, 11, e022937.	1.6	26
3	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. <i>Journal of the American Heart Association</i> , 2022, 11, e024999.	1.6	13
4	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1660-1671.	1.2	36
5	Reduction in Revascularization With Icosapent Ethyl. <i>Circulation</i> , 2021, 143, 33-44.	1.6	46
6	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e61-e63.	1.4	23
7	The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. <i>Journal of Clinical Lipidology</i> , 2021, 15, 33-60.	0.6	105
8	Dyslipidemia in Patients with Kidney Disease. <i>Cardiology Clinics</i> , 2021, 39, 353-363.	0.9	14
9	Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. <i>Journal of Clinical Lipidology</i> , 2021, 15, 629-648.	0.6	69
10	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1525-1537.	1.2	25
11	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021, 144, 1845-1855.	1.6	39
12	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. <i>Circulation</i> , 2021, 144, 1750-1759.	1.6	36
13	REDUCE-IT USA. <i>Circulation</i> , 2020, 141, 367-375.	1.6	104
14	Authors' response to letter by Anagnostis and Stevenson, "Is there a role for menopausal hormone therapy in a woman with increased lipoprotein(a) concentrations?" <i>Journal of Clinical Lipidology</i> , 2020, 14, 156-157.	0.6	0
15	JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. <i>Journal of Clinical Lipidology</i> , 2020, 14, 4-15.	0.6	3
16	Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. <i>Journal of Clinical Lipidology</i> , 2020, 14, 88-97.e2.	0.6	12
17	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2020, 14, 398-413.	0.6	70
18	Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. <i>Circulation</i> , 2019, 140, e673-e691.	1.6	282

#	ARTICLE	IF	CITATIONS
19	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1159-1161.	1.2	79
20	Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. <i>Journal of Clinical Lipidology</i> , 2019, 13, 586-593.e5.	0.6	11
21	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. <i>Journal of Clinical Lipidology</i> , 2019, 13, 860-872.	0.6	79
22	Effects of Icosapent Ethyl on Total Ischemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	1.2	208
23	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019, 13, 374-392.	0.6	315
24	The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 415-424.	0.6	33
25	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019, 380, 11-22.	13.9	2,153
26	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e38-e81.	1.1	431
27	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	1.0	262
28	Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. <i>Journal of Clinical Lipidology</i> , 2018, 12, 78-88.	0.6	22
29	Safety and efficacy of statin therapy. <i>Nature Reviews Cardiology</i> , 2018, 15, 757-769.	6.1	239
30	Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. <i>Current Atherosclerosis Reports</i> , 2017, 19, 29.	2.0	11
31	The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 179-186.	1.3	89
32	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2017, 11, 880-890.	0.6	85
33	Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2017, 11, 891-900.	0.6	49
34	Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease. <i>Circulation</i> , 2017, 135, e867-e884.	1.6	484
35	Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial. <i>Clinical Cardiology</i> , 2017, 40, 138-148.	0.7	154
36	Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ) Patient, 2017, 10, 321-334.	1.1	9

#	ARTICLE	IF	CITATIONS
37	Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins. Evidence-Based Medicine, 2017, 22, 210-210.	0.6	3
38	Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy. Journal of the American College of Cardiology, 2017, 70, 1680-1681.	1.2	27
39	Metabolic syndrome is associated with muscle symptoms among statin users. Journal of Clinical Lipidology, 2016, 10, 1022-1029.	0.6	16
40	Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. Journal of Clinical Lipidology, 2016, 10, 833-841.	0.6	92
41	Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovascular Drugs and Therapy, 2016, 30, 305-313.	1.3	30
42	Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surgery for Obesity and Related Diseases, 2016, 12, 468-495.	1.0	45
43	New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk. Endocrinology and Metabolism Clinics of North America, 2016, 45, 17-37.	1.2	22
44	National Lipid Association Annual Summary of Clinical Lipidology 2016. Journal of Clinical Lipidology, 2016, 10, S1-S43.	0.6	99
45	Effect of Pharmacist Counseling Intervention on Health Care Utilization Following Hospital Discharge: A Randomized Control Trial. Journal of General Internal Medicine, 2016, 31, 470-477.	1.3	58
46	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. Journal of Clinical Lipidology, 2016, 10, 33-57.	0.6	39
47	Beta-human Chorionic Gonadotropin-producing Renal Cell Carcinoma. American Journal of Medicine, 2016, 129, e29-e31.	0.6	2
48	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. Journal of Clinical Lipidology, 2016, 10, 15-32.	0.6	17
49	Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. Journal of Clinical Lipidology, 2015, 9, 758-769.	0.6	390
50	Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	1.0	1,024
51	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology, 2015, 9, S1-S122.e1.	0.6	430
52	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. Journal of Clinical Lipidology, 2015, 9, 129-169.	0.6	632
53	New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk. Cardiology Clinics, 2015, 33, 181-196.	0.9	24
54	The CardioMetabolic Health Alliance. Journal of the American College of Cardiology, 2015, 66, 1050-1067.	1.2	211

#	ARTICLE	IF	CITATIONS
55	Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. <i>Clinical Lipidology</i> , 2014, 9, 149-161.	0.4	4
56	Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. <i>Journal of Clinical Lipidology</i> , 2014, 8, 554-561.	0.6	128
57	National Lipid Association Annual Summary of Clinical Lipidology 2015. <i>Journal of Clinical Lipidology</i> , 2014, 8, S1-S36.	0.6	64
58	Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: A subanalysis of the USAGE study. <i>Journal of Clinical Lipidology</i> , 2014, 8, 69-76.	0.6	40
59	Low literacy is associated with uncontrolled blood pressure in primary care patients with hypertension and heart disease. <i>Patient Education and Counseling</i> , 2014, 96, 165-170.	1.0	61
60	Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia. <i>American Journal of Medicine</i> , 2014, 127, 36-44.e1.	0.6	62
61	National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary. <i>Journal of Clinical Lipidology</i> , 2014, 8, 473-488.	0.6	396
62	An assessment by the Statin Muscle Safety Task Force: 2014 update. <i>Journal of Clinical Lipidology</i> , 2014, 8, S58-S71.	0.6	391
63	NLA Task Force on Statin Safety - 2014 update. <i>Journal of Clinical Lipidology</i> , 2014, 8, S1-S4.	0.6	114
64	An assessment by the Statin Intolerance Panel: 2014 update. <i>Journal of Clinical Lipidology</i> , 2014, 8, S72-S81.	0.6	135
65	Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. <i>Atherosclerosis</i> , 2014, 235, 585-591.	0.4	53
66	Effect of health information technology interventions on lipid management in clinical practice: A systematic review of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2013, 7, 546-560.	0.6	34
67	Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis. <i>Evidence-Based Medicine</i> , 2013, 18, 175-176.	0.6	0
68	Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. <i>Journal of Clinical Lipidology</i> , 2013, 7, 102-108.	0.6	34
69	Lipoprotein(a), Cardiovascular Disease, and Contemporary Management. <i>Mayo Clinic Proceedings</i> , 2013, 88, 1294-1311.	1.4	87
70	Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: Proceedings from a workshop. <i>Journal of Clinical Lipidology</i> , 2013, 7, 573-609.	0.6	22
71	Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient education. <i>Journal of Clinical Lipidology</i> , 2013, 7, 472-483.	0.6	210
72	Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. <i>Journal of Clinical Lipidology</i> , 2013, 7, 399-407.	0.6	22

#	ARTICLE	IF	CITATIONS
73	Achieving adherence to lipid-lowering regimens. <i>Journal of Clinical Lipidology</i> , 2013, 7, 4-13.	0.6	5
74	Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin. <i>Current Medical Research and Opinion</i> , 2013, 29, 773-781.	0.9	2
75	A new pure Î‰-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 687-695.	0.6	8
76	Effect of a Pharmacist Intervention on Clinically Important Medication Errors After Hospital Discharge. <i>Annals of Internal Medicine</i> , 2012, 157, 1.	2.0	271
77	Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. <i>Journal of Clinical Lipidology</i> , 2012, 6, 5-18.	0.6	229
78	Hospital use and medical care costs up to 5 years after triglyceride lowering among patients with severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2012, 6, 443-449.	0.6	8
79	Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. <i>Journal of Clinical Lipidology</i> , 2012, 6, 208-215.	0.6	395
80	Authors' reply to commentary entitled "EPA and DHA: Distinct yet essential n-3 fatty acids". <i>Journal of Clinical Lipidology</i> , 2012, 6, 477-479.	0.6	2
81	Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2012, 6, 450-461.	0.6	54
82	Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials. <i>American Journal of Cardiology</i> , 2012, 110, 1468-1476.	0.7	108
83	Improving Medication Adherence through Graphically Enhanced Interventions in Coronary Heart Disease (IMAGE-CHD): A Randomized Controlled Trial. <i>Journal of General Internal Medicine</i> , 2012, 27, 1609-1617.	1.3	63
84	Opening a New Lipid "Apo-theater": Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. <i>Mayo Clinic Proceedings</i> , 2011, 86, 762-780.	1.4	32
85	Non-High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification. <i>Journal of the American College of Cardiology</i> , 2011, 58, 457-463.	1.2	132
86	Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Low-Density Lipoprotein Cholesterol: A Critical Review. <i>Journal of Clinical Lipidology</i> , 2011, 5, 200-201.	0.6	4
87	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	0.6	235
88	Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis. <i>Current Atherosclerosis Reports</i> , 2011, 13, 474-483.	2.0	246
89	Estimating Health and Economic Benefits from Using Prescription Omega-3 Fatty Acids in Patients With Severe Hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2011, 108, 691-697.	0.7	13
90	Statin-induced myopathy: a review and update. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 373-387.	1.0	248

#	ARTICLE	IF	CITATIONS
91	Avoiding statin myopathy: understanding key drug interactions. <i>Clinical Lipidology</i> , 2011, 6, 665-674.	0.4	15
92	Development and evaluation of a medication counseling workshop for physicians: can we improve on "take two pills and call me in the morning"? <i>Medical Education Online</i> , 2011, 16, 7133.	1.1	17
93	Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. <i>Clinical Lipidology</i> , 2011, 6, 131-136.	0.4	4
94	Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies. <i>Clinical Cardiology</i> , 2010, 33, 609-619.	0.7	7
95	Association of age, health literacy, and medication management strategies with cardiovascular medication adherence. <i>Patient Education and Counseling</i> , 2010, 81, 177-181.	1.0	113
96	Omega-3 Fatty Acids for Cardiovascular Disease Prevention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 365-380.	0.4	44
97	Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment. <i>Current Atherosclerosis Reports</i> , 2010, 12, 34-42.	2.0	16
98	Evidence-Based Management of Statin Myopathy. <i>Current Atherosclerosis Reports</i> , 2010, 12, 322-330.	2.0	70
99	30-Year Trends in Serum Lipids Among United States Adults: Results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. <i>American Journal of Cardiology</i> , 2010, 106, 969-975.	0.7	133
100	Health literacy and the quality of physician-patient communication during hospitalization. <i>Journal of Hospital Medicine</i> , 2010, 5, 269-275.	0.7	100
101	Continuing Medical Education Program in the Journal of Hospital Medicine. <i>Journal of Hospital Medicine</i> , 2010, 5, 268-268.	0.7	0
102	Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. <i>Clinical Lipidology</i> , 2010, 5, 627-649.	0.4	2
103	Rationale and Design of the Pharmacist Intervention for Low Literacy in Cardiovascular Disease (PILL-CVD) Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 212-219.	0.9	58
104	Using Apolipoprotein B to Manage Dyslipidemic Patients: Time for a Change?. <i>Mayo Clinic Proceedings</i> , 2010, 85, 440-445.	1.4	52
105	A "Hot" Topic in Dyslipidemia Management "How to Beat a Flush": Optimizing Niacin Tolerability to Promote Long-term Treatment Adherence and Coronary Disease Prevention. <i>Mayo Clinic Proceedings</i> , 2010, 85, 365-379.	1.4	37
106	Using Apolipoprotein B to Manage Dyslipidemia "Reply". <i>Mayo Clinic Proceedings</i> , 2010, 85, 769-771.	1.4	1
107	Omega-3 Fatty Acids. , 2009, , 326-338.		9
108	Inhaled anticholinergics and the long-term treatment of chronic obstructive pulmonary disease: Weighing benefits and risks. <i>Clinical Cornerstone</i> , 2009, 9, 45-49.	1.0	0

#	ARTICLE	IF	CITATIONS
109	Chronic kidney disease and statins: Improving cardiovascular outcomes. <i>Current Atherosclerosis Reports</i> , 2009, 11, 301-308.	2.0	8
110	Development and Evaluation of the Adherence to Refills and Medications Scale (ARMS) among Low-Literacy Patients with Chronic Disease. <i>Value in Health</i> , 2009, 12, 118-123.	0.1	286
111	Meta-Analysis of the Relationship Between Non-High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk. <i>Journal of the American College of Cardiology</i> , 2009, 53, 316-322.	1.2	327
112	Myopathy with statin-fibrate combination therapy: clinical considerations. <i>Nature Reviews Endocrinology</i> , 2009, 5, 507-518.	4.3	72
113	Effect of baseline plasma fatty acids on eicosapentaenoic acid levels in individuals supplemented with α -linolenic acid. <i>International Journal of Food Sciences and Nutrition</i> , 2009, 60, 28-37.	1.3	1
114	Managing Dyslipidemia in Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2375-2384.	1.2	164
115	The importance of non-HDL cholesterol reporting in lipid management. <i>Journal of Clinical Lipidology</i> , 2008, 2, 267-273.	0.6	145
116	Effects of Niacin on Glucose Control in Patients With Dyslipidemia. <i>Mayo Clinic Proceedings</i> , 2008, 83, 470-478.	1.4	101
117	Toward "Pain-Free" Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. <i>Mayo Clinic Proceedings</i> , 2008, 83, 687-700.	1.4	83
118	Medication Use Among Inner-City Patients After Hospital Discharge: Patient-Reported Barriers and Solutions. <i>Mayo Clinic Proceedings</i> , 2008, 83, 529-535.	1.4	90
119	Fluvastatin, Rhabdomyolysis, and Myotoxicity. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1296-1297.	1.4	3
120	Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1316-1325.	1.4	22
121	Fluvastatin, Rhabdomyolysis, and Myotoxicity—Reply. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1297.	1.4	4
122	Clinical characterization and molecular mechanisms of statin myopathy. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 955-969.	0.6	45
123	Medication Use Among Inner-City Patients After Hospital Discharge: Patient-Reported Barriers and Solutions. <i>Mayo Clinic Proceedings</i> , 2008, 83, 529-535.	1.4	121
124	Toward "Pain-Free" Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. <i>Mayo Clinic Proceedings</i> , 2008, 83, 687-700.	1.4	136
125	Initiating statins in the elderly: the evolving challenge. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008, 15, 182-187.	1.2	9
126	Role of ω -3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 1981S-1990S.	2.2	125

#	ARTICLE	IF	CITATIONS
127	Clinical research in low-literacy populations: using teach-back to assess comprehension of informed consent and privacy information. <i>IRB: Ethics & Human Research</i> , 2008, 30, 13-9.	0.8	79
128	Development and Psychometric Evaluation of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) in Low-Literacy Patients With Chronic Disease. <i>Journal of Nursing Measurement</i> , 2007, 15, 203-219.	0.2	210
129	The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. <i>Current Opinion in Lipidology</i> , 2007, 18, 401-408.	1.2	203
130	Low-Literacy Interventions to Promote Discussion of Prostate Cancer. <i>American Journal of Preventive Medicine</i> , 2007, 33, 83-90.	1.6	39
131	Hypertriglyceridemia and cardiovascular risk reduction. <i>Clinical Therapeutics</i> , 2007, 29, 763-777.	1.1	113
132	Safety Considerations with Fibrate Therapy. <i>American Journal of Cardiology</i> , 2007, 99, S3-S18.	0.7	332
133	Safety Considerations with Gastrointestinally Active Lipid-Lowering Drugs. <i>American Journal of Cardiology</i> , 2007, 99, S47-S55.	0.7	81
134	Beyond lipids: The role of omega-3 fatty acids from fish oil in the prevention of coronary heart disease. <i>Current Atherosclerosis Reports</i> , 2007, 9, 145-153.	2.0	33
135	Patient Literacy and Question-asking Behavior During the Medical Encounter: A Mixed-methods Analysis. <i>Journal of General Internal Medicine</i> , 2007, 22, 782-786.	1.3	242
136	Development of an illustrated medication schedule as a low-literacy patient education tool. <i>Patient Education and Counseling</i> , 2007, 66, 368-377.	1.0	174
137	The Safety of Aggressive Statin Therapy: How Much Can Low-Density Lipoprotein Cholesterol Be Lowered?. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1225-1231.	1.4	23
138	Overcoming Ageism Bias in the Treatment of Hypercholesterolaemia. <i>Drug Safety</i> , 2006, 29, 421-448.	1.4	48
139	Fibrates in Combination With Statins in the Management of Dyslipidemia. <i>Journal of Clinical Hypertension</i> , 2006, 8, 35-41.	1.0	52
140	Flaxseed Oil Increases the Plasma Concentrations of Cardioprotective (n-3) Fatty Acids in Humans. <i>Journal of Nutrition</i> , 2006, 136, 83-87.	1.3	164
141	Development and Implementation of a Health Literacy Training Program for Medical Residents. <i>Medical Education Online</i> , 2006, 11, 4612.	1.1	41
142	Predictors of medication self-management skill in a low-literacy population. <i>Journal of General Internal Medicine</i> , 2006, 21, 852-856.	1.3	191
143	Quality of Care in African-American Patients Admitted for Congestive Heart Failure at a University Teaching Hospital. <i>American Journal of Cardiology</i> , 2006, 97, 690-693.	0.7	15
144	Statin Safety: Lessons from New Drug Applications for Marketed Statins. <i>American Journal of Cardiology</i> , 2006, 97, S44-S51.	0.7	122

#	ARTICLE	IF	CITATIONS
145	Statin Safety: An Assessment Using an Administrative Claims Database. <i>American Journal of Cardiology</i> , 2006, 97, S61-S68.	0.7	111
146	Secondary Prevention of Coronary Artery Disease with Omega-3 Fatty Acids. <i>American Journal of Cardiology</i> , 2006, 98, 61-70.	0.7	53
147	Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force. <i>American Journal of Cardiology</i> , 2006, 97, S89-S94.	0.7	370
148	Comparison of African-American Patients With Systolic Heart Failure Versus Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2006, 98, 806-808.	0.7	13
149	Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study. <i>Current Medical Research and Opinion</i> , 2006, 22, 1065-1073.	0.9	26
150	Usefulness of Omega-3 Fatty Acids and the Prevention of Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2005, 96, 1521-1529.	0.7	139
151	Identifying and Assisting Low-Literacy Patients with Medication Use: A Survey of Community Pharmacies. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1441-1445.	0.9	70
152	Cost-Effectiveness of Fluvastatin following Successful First Percutaneous Coronary Intervention. <i>Annals of Pharmacotherapy</i> , 2005, 39, 610-616.	0.9	7
153	Effects of race on Lipid-Lowering management in hospitalized patients with coronary heart disease. <i>American Journal of Cardiology</i> , 2004, 93, 1167-1170.	0.7	6
154	Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. <i>American Journal of Cardiology</i> , 2004, 94, 1140-1146.	0.7	221
155	Fluvastatin. <i>Drugs</i> , 2004, 64, 1305-1323.	4.9	23
156	Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. <i>American Journal of Cardiology</i> , 2003, 91, 1134-1136.	0.7	6
157	Risk for Myopathy With Statin Therapy in High-Risk Patients. <i>Archives of Internal Medicine</i> , 2003, 163, 553.	4.3	404
158	Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 269-286.	1.0	15
159	An assessment of obesity among African-American women in an inner city primary care clinic. <i>Journal of the National Medical Association</i> , 2002, 94, 1049-57.	0.6	9
160	Introduction. <i>American Journal of Medicine</i> , 2001, 110, 1-2.	0.6	40
161	Clinical context: Current concepts of coronary heart disease management. <i>American Journal of Medicine</i> , 2001, 110, 3-11.	0.6	35
162	Combination lipid-altering therapy: An emerging treatment paradigm for the 21st century. <i>Current Atherosclerosis Reports</i> , 2001, 3, 373-382.	2.0	23

#	ARTICLE	IF	CITATIONS
163	The Fats of Life. Archives of Internal Medicine, 2001, 161, 2185.	4.3	171
164	Treating isolated low high-density lipoprotein cholesterol: prescient or premature?. American Journal of Cardiology, 2000, 85, 484-486.	0.7	6
165	Impact of Evidence-Based "Clinical Judgment" on the Number of American Adults Requiring Lipid-Lowering Therapy Based on Updated NHANES III Data. Archives of Internal Medicine, 2000, 160, 1361.	4.3	70
166	Use of a Low-Literacy Patient Education Tool to Enhance Pneumococcal Vaccination Rates. JAMA - Journal of the American Medical Association, 1999, 282, 646.	3.8	130
167	New Perspectives on the Management of Low Levels of High-Density Lipoprotein Cholesterol. Archives of Internal Medicine, 1999, 159, 1049.	4.3	60
168	Maximizing the Cost-effectiveness of Lipid-Lowering Therapy. Archives of Internal Medicine, 1998, 158, 1977.	4.3	69
169	Improving the Cost Effectiveness of Lipid Lowering Therapy in Coronary Heart Disease Prevention. Medical Science Symposia Series, 1998, , 275-284.	0.0	0
170	Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease. Current Opinion in Lipidology, 1997, 8, 369-374.	1.2	19
171	Changes in Plasma Cholesterol Levels after Hospitalization for Acute Coronary Events. Cardiology, 1996, 87, 194-199.	0.6	30
172	Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitor Therapy in the Managed Care Era. American Journal of Cardiology, 1996, 78, 32-41.	0.7	20
173	Efficacy and Safety of Pravastatin in African Americans With Primary Hypercholesterolemia. Archives of Internal Medicine, 1995, 155, 1900.	4.3	22
174	Fluvastatin with and without niacin for hypercholesterolemia. American Journal of Cardiology, 1994, 74, 149-154.	0.7	88
175	Combination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary report on safety. American Journal of Cardiology, 1994, 73, D25-D29.	0.7	26
176	Fluvastatin and niacin in hypercholesterolemia: A preliminary report on gender differences in efficacy. American Journal of Medicine, 1994, 96, S64-S68.	0.6	16
177	Long-term treatment of hypercholesterolemia with dietary fiber. American Journal of Medicine, 1994, 97, 504-508.	0.6	52
178	Combination drug therapy for hyperlipidemia. Clinical Cardiology, 1994, 17, IV-28-IV-34.	0.7	0
179	Formulary policy for cholesterol reduction. Journal of General Internal Medicine, 1991, 6, 266-267.	1.3	0
180	Quitting Smoking: Nicotine vs Placebo Gum. JAMA - Journal of the American Medical Association, 1989, 262, 773.	3.8	0

#	ARTICLE	IF	CITATIONS
181	Primary Prevention With Metoprolol in Patients With Hypertension. JAMA - Journal of the American Medical Association, 1988, 260, 1715.	3.8	1